High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma

Journal of Medical Virology

Volumn 88, Issue 6, 2016, Pages 1010-1017

  Cho, Yuri ^a   Yu, Su Jong ^a   Cho, Eun Ju ^a   Lee, Jeong Hoon ^a   Kim, Tae Min ^a   Heo, Dae Seog ^a   Kim, Yoon Jun ^a   Yoon, Jung Hwan ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Anti HBs; Lymphoma; Reactivation; Resolved hepatitis B; Rituximab

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENTECAVIR; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; PREDNISOLONE; PREDNISONE; RITUXIMAB; SERUM ALBUMIN; TELBIVUDINE; TENOFOVIR; VINCRISTINE; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; HEPATITIS B ANTIBODY; VIRUS DNA;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CANCER CHEMOTHERAPY; CHILD PUGH SCORE; COHORT ANALYSIS; DEATH; DECOMPENSATED LIVER CIRRHOSIS; DISEASE EXACERBATION; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HEPATORENAL SYNDROME; HOSPITAL ADMISSION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LARGE CELL LYMPHOMA; LIVER CIRRHOSIS; LYMPHOCYTOMA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MIDDLE AGED; MORTALITY; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PROGNOSIS; RETROSPECTIVE STUDY; SEPSIS; SEROCONVERSION; VIRUS LOAD; VIRUS REACTIVATION; BLOOD; COMPLICATION; DRUG EFFECTS; EPIDEMIOLOGY; GENETICS; HEPATITIS B VIRUS; IMMUNOLOGY; LYMPHOMA, NON-HODGKIN; PHYSIOLOGY; SEROLOGY; SOUTH KOREA; VERY ELDERLY; VIROLOGY; VIRUS ACTIVATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RITUXIMAB; SEROLOGIC TESTS; VIRUS ACTIVATION;

EID: 84962019263     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.24423     Document Type: Article

References (36)

1. Becker U, Deis A, Sorensen TI, Gronbaek M, Borch-Johnsen K, Muller CF, Schnohr P, Jensen G. 1996. Prediction of risk of liver disease by alcohol intake, sex, and age: A prospective population study. Hepatology 23:1025-1029.
2. Bel'eed K, Wright M, Eadington D, Farr M, Sellars L. 2002. Vaccination against hepatitis B infection in patients with end stage renal disease. Postgrad Med J 78:538-540.
3. Chan TM, Fang GX, Tang CS, Cheng IK, Lai KN, Ho SK. 2002. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology 36:1246-1252.
4. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. 1999. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244.
5. Cooper CL, Angel JB, Seguin I, Davis HL, Cameron DW. 2008. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. Clin Infect Dis 46:1310-1314.
6. Cornberg M, Protzer U, Petersen J, Wedemeyer H, Berg T, Jilg W, Erhardt A, Wirth S, Sarrazin C, Dollinger MM, Schirmacher P, Dathe K, Kopp IB, Zeuzem S, Gerlich WH, Manns Awmf MP. 2011. [Prophylaxis, diagnosis and therapy of hepatitis B virus infection-the German guideline]. Z Gastroenterol 49:871-930.
7. Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, Jonas C, Klippenstein D, Dallaire B, Varns C. 1999. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268-276.
8. Dong HJ, Ni LN, Sheng GF, Song HL, Xu JZ, Ling Y. 2013. Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: A meta-analysis. J Clin Virol 57:209-214.
9. European Association For The Study Of The L. 2012. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 57:167-185.
10. Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, Dai MS, Chiu BC, Fintel B, Cheng Y, Chuang SS, Lee MY, Chen TY, Lin SF, Kuo CY. 2011. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: Meta-analysis and examination of FDA safety reports. Ann Oncol 22:1170-1180.
11. Fukushima N, Mizuta T, Tanaka M, Yokoo M, Ide M, Hisatomi T, Kuwahara N, Tomimasu R, Tsuneyoshi N, Funai N, Sueoka E. 2009. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol 20:2013-2017.
12. Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC, Lin SF, Lin TH, Hsiao HH, Young JH, Chang MC, Liao YM, Li CC, Wu HB, Tien HF, Chao TY, Liu TW, Cheng AL, Chen PJ. 2008. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial. Hepatology 47:844-853.
13. Huang YH, Hsiao LT, Hong YC, Chiou TJ, Yu YB, Gau JP, Liu CY, Yang MH, Tzeng CH, Lee PC, Lin HC, Lee SD. 2013. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 31:2765-2772.
14. Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, Leung N, Luk JM, Lie AK, Kwong YL, Liang R, Lau GK. 2006. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 131:59-68.
15. Keam B, Lee JH, Im SA, Yoon JH. 2011. Why, when, and how to prevent hepatitis B virus reactivation in cancer patients undergoing chemotherapy. J Natl Compr Canc Netw 9:465-477.
16. Kusumoto S, Tanaka Y, Mizokami M, Ueda R. 2009. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 90:13-23.
17. Lalazar G, Rund D, Shouval D. 2007. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 136:699-712.
18. Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, Cheung M, Zhang HY, Lie A, Ngan R, Liang R. 2003. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 125:1742-1749.
19. Li W, Huang L, Guo H, Wei X, Liang Z. 2014. Antiviral efficacy analysis of telbivudine concurrent with the first cycle of chemotherapy in HBsAg-positive lymphoma patients. J Clin Virol 61:199-203.
20. Lim SH, Beers SA, French RR, Johnson PW, Glennie MJ, Cragg MS. 2010. Anti-CD20 monoclonal antibodies: Historical and future perspectives. Haematologica 95:135-143.
21. Liu CJ, Kao JH, Chen DS. 2006. Kinetics of hepatitis B virus reactivation after chemotherapy: More questions than answers. Gastroenterology 131:1656. author reply 1656-1657.
22. Lok AS, McMahon BJ. 2009. Chronic hepatitis B: Update 2009. Hepatology 50:661-662.
23. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, Csako G. 2008. Systematic review: The effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 148:519-528.
24. Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P, Caraceni P, Daniele B, Di Marco V, Fabrizi F, Fagiuoli S, Grossi P, Lampertico P, Meliconi R, Mangia A, Puoti M, Raimondo G, Smedile A. 2007. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 39:397-408.
25. Mozessohn L, Chan KK, Feld JJ, Hicks LK. 2015. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: A meta-analysis. J Viral Hepat 22:842-849.
26. Niitsu N, Hagiwara Y, Tanae K, Kohri M, Takahashi N. 2010. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy. J Clin Oncol 28:5097-5100.
27. Oh MJ, Lee HJ. 2013. A study of hepatitis B virus reactivation associated with rituximab therapy in real-world clinical practice: A single-center experience. Clin Mol Hepatol 19:51-59.
28. Pei SN, Ma MC, Wang MC, Kuo CY, Rau KM, Su CY, Chen CH. 2012. Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy. Ann Hematol 91:1007-1012.
29. Qurishi N, Kreuzberg C, Luchters G, Effenberger W, Kupfer B, Sauerbruch T, Rockstroh JK, Spengler U. 2003. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 362:1708-1713.
30. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, SS M, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M, Investigators AC. 2006. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 43:1317-1325.
31. Thio CL, Seaberg EC, Skolasky R, Jr., Phair J, Visscher B, Munoz A, Thomas DL, Multicenter ACS. 2002. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 360:1921-1926.
32. Wang CW, Wang LC, Chang MH, Ni YH, Chen HL, Hsu HY, Chen DS. 2005. Long-term follow-up of Hepatitis B Surface antibody levels in subjects receiving universal Hepatitis B vaccination in infancy in an area of hyperendemicity: Correlation between radioimmunoassay and enzyme immunoassay. Clin Diagn Lab Immunol 12:1442-1447.
33. Yeo W, Chan PK, Chan HL, Mo FK, Johnson PJ. 2001. Hepatitis B virus reactivation during cytotoxic chemotherapy-enhanced viral replication precedes overt hepatitis. J Med Virol 65:473-477.
34. Yeo W, Chan PK, Ho WM, Zee B, Lam KC, Lei KI, Chan AT, Mok TS, Lee JJ, Leung TW, Zhong S, Johnson PJ. 2004. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 22:927-934.
35. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, Hui EP, Lei KI, Mok TS, Chan PK. 2009. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 27:605-611.
36. Yeo W, Johnson PJ. 2006. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 43:209-220.